Trial Profile
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Chronic myelomonocytic leukaemia
- Focus Therapeutic Use
- 13 Dec 2022 Results (n=29) assessing efficacy and safety of ruxolitinib, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 09 Jun 2022 Planned primary completion date changed from 1 May 2023 to 19 Sep 2023.
- 09 Jun 2022 Status changed from recruiting to active, no longer recruiting.